Abstract: Devices and methods described herein facilitate rapid wireless recharging, while reducing risk of injury, damage, or discomfort caused by heat generated during recharging. The embodiments described herein are useful in a variety of context, including for IoT devices, personal electronics, electric vehicles, and medical devices, among others. Such devices can prevent localized overheating of the device.

Abstract: Selection strategies for a direct marketing campaign that identifies consumers from a credit bureau or other consumer database are refined on a stable subset of the credit database. Once refined, consumer selection criteria may be used to execute the direct marketing campaign on the full consumer/credit database. The data for the test database represents a random sampling of approximately 10% of the full database and the sampling is regenerated approximately weekly in order to provide a stable set of data on which campaign developers test their campaign. For each consumer in the sampling, the environment allows a client to access and use attributes calculated by the credit bureau and proprietary attributes and data owned by the client. The system allows for a plurality of clients to use the system substantially simultaneously while protecting the privacy and integrity of the client's proprietary data and results.

Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Abstract: Chips and metallic nanostructure biosensors comprising a dielectric substrate and discontinuous and disordered metallic nanostructures of flat island shapes thereon are disclosed herein. Also disclosed are methods of making and using the same.

Abstract: A method includes buffering, in a descriptor queue, descriptors associated with translation units of an LBA-based, direct memory access (DMA) read command of a host system, each descriptor to be linked with a pointer including a physical destination for data associated with a respective translation unit. The method includes sending address translation requests to an address translation circuit for the pointers of respective translation units and detecting an address translation request miss at a cache of the address translation circuit for a first pointer of a first translation unit linked to a first descriptor of the plurality of descriptors. The method includes causing a translation miss message to be sent to a page request interface (PRI) handler, the translation miss message containing a virtual address of the first pointer and to trigger the PRI handler to send a page miss request to a translation agent of the host system.

Abstract: A method, performed by pointer fetch circuitry, includes buffering, in a pointer buffer of host interface circuitry, pointers associated with chop commands of a logical block address read command residing in a submission queue of a host system. The method includes sending address translation requests to an address translation circuit for respective translation units of respective chop commands, each translation unit includes a subset of the pointers. The method includes detecting an address translation request miss at a cache of the address translation circuit for a translation unit of a chop command. The method includes sending a translation miss message to a page request interface (PRI) handler. The translation miss message contains a virtual address of the translation unit and a restart point for the chop command, the translation miss message to trigger the PRI handler to send a page miss request to a translation agent of the host system.

Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Abstract: In one aspect, the disclosure relates to catalysts for electrochemical water splitting, in particular catalysts useful for oxygen evolution at an anode in electrochemical water splitting. The disclosed catalysts compositions comprise a catalyst core component, a shell component, and optionally a catalyst outer component; wherein the catalyst core component comprises a composition having the chemical formula MxPy; where M is a transition metal; wherein x is a number from about 1 to about 20; wherein y is a number from about 1 to about 20; wherein the shell component comprises a conducting polymer; and wherein the catalyst outer component is a transition metal that is not the same as the transition metal M. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Abstract: In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I?) forms.

Abstract: Devices, systems, and techniques for controlling charging power transmitted to an implantable medical device during a recharging process based on patient activity are disclosed. Various example techniques include a method comprising receiving, by processing circuitry, an activity signal generated by an implantable medical device and indicative of an activity level of a patient during charging of a rechargeable power source of the implantable medical device implanted in the patient, determining, by the processing circuitry and based on the activity signal, a patient status for the patient during charging of the rechargeable power source, and controlling, by the processing circuitry and based on the patient status, charging of the rechargeable power source of the implantable medical device.

Abstract: The invention provides, inter alia, ultra-thin conformal coated biological surfaces, such as living cells, cell clusters, tissues, organs, and hybrid synthetic organs, and methods of making the same, e.g., using click reactive water soluble polymers, under conditions that do not damage or significantly modify the biological surfaces. In some embodiments, the coated biological surfaces are suitable for delivery to a subject in need thereof.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Abstract: In one embodiment, an authorizing device (e.g., a gateway) receives a native protocol request packet from a requesting device destined to a serving device, and translates the native protocol request packet into an authorization protocol mapping. The authorizing device may then apply authorization protocol based authorization (e.g., OT protocol independent) to the native protocol request packet based on the authorization protocol mapping, and transmits the native protocol request packet toward the serving device in response to the authorization protocol mapping being authorized. In one embodiment, the techniques herein may also perform an audit in this manner.

Abstract: A system includes a memory device and a processing device, operatively coupled with the memory device, to perform operations including: receiving a request to modify one or more regions of the memory device; identifying one or more mapping structures associated with each region of the one or more regions of the memory device; determining that a counter satisfies a threshold criterion, wherein the counter indicates a number of memory access commands at the one or more regions; creating a copy of each mapping structure associated with each region; and modifying the copy of each mapping structure according to the request to modify the one or more regions of the memory device.

Abstract: Devices, systems, and techniques are described to detect when a power transmitting and receiving system is in an inefficient position, which may cause a thermal response that less desirable than a more efficient position. The system may power transmitting device configured to wirelessly transfer electromagnetic energy to a power receiving device. Processing circuitry of the system may compute a target output power deliverable by the power transmitting device for a first duration and control the power transmitting device to output the target output power based in part on a heat limit. The processing circuitry may further calculate an energy transfer efficiency to the power receiving unit, update an adjustment factor based on the calculated energy transfer efficiency, and apply the adjustment factor to the heat limit for a subsequent duration.

Abstract: A device includes an address translation circuit of host interface circuitry to handle address translation requests to a host system from a host queue interface circuit. The address translation circuit includes cache to store address translations associated with the address translation requests. The host queue interface circuit, coupled to the address translation circuit, is to: pause command fetch arbitration on a submission queue of the host system that is targeted by an address translation request that missed at the cache; trigger a page request interface (PRI) handler to send a page miss request to a translation agent (TA) of the host, the page miss request including a virtual address of the address translation request; receive a restart message from the PRI handler upon the PRI handler receiving a page miss response from the TA; and restart command arbitration on the submission queue that was paused responsive to the restart message.

Abstract: A processing device includes host interface circuitry to interact with a host system and an address translation circuit to handle address translation requests to the host system from host interface circuits. The address translation circuit includes a cache to store address translations associated with the address translation requests for future access by host interface circuits. A page request interface (PRI) handler tracks translation miss messages received from the host interface circuits, each translation miss message including a virtual address of a miss at the cache. The PRI handler removes duplicate translation miss messages having an identical virtual address and creates page miss requests from non-duplicate translation miss messages that are categorized into page request groups, each page request group corresponding to a host interface circuit of the host interface circuits. The PRI handler queues the page request groups to be sent to a translation agent of the host system.

Abstract: Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.